Form 4: PRO DEX Director Receives Restricted Stock Grant

PRO DEX Director William James Farrell III was granted 1,000 restricted shares of common stock, vesting over five years, aligning his interests with shareholders.

Summary

• William James Farrell III, a Director of PRO DEX INC (PDEX), acquired 1,000 shares of Common Stock on November 20, 2025.
• The shares were granted under the Issuer's 2016 Equity Incentive Plan at a price of $0.00 per share.
• These restricted shares will vest in equal installments over five years, contingent on Mr. Farrell's continued service to Pro-Dex, Inc.
• Following this transaction, Mr. Farrell directly owns 2,000 shares of Common Stock and indirectly owns 5,100 shares through an IRA.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a standard compensation practice and generally viewed as a positive for aligning management interests with shareholders, but does not indicate any significant operational or financial news.

Positives

• The grant of restricted shares aligns the director's long-term interests with those of shareholders, promoting sustained performance.
• The equity incentive plan is a common mechanism to attract and retain key personnel.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the granted shares is subject to the future market price fluctuations of PRO DEX INC common stock.
• Vesting is contingent on continued service, meaning the shares could be forfeited if the director's service ends prematurely.

Future Outlook

The vesting schedule over five years indicates an expectation of continued service from Director William James Farrell III, aligning his incentives with the company's long-term performance.

Industry Context

Equity grants, particularly restricted stock units with vesting schedules, are a standard component of executive and director compensation packages across various industries. This practice aims to align the interests of company leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of restricted shares to a director is a common form of non-cash compensation, consistent with practices at many publicly traded companies.
• The five-year vesting schedule is a typical duration designed to promote long-term retention and performance alignment, comparable to similar plans at companies like Medtronic (MDT) or Stryker (SYK) in the medical device sector, which often use multi-year vesting for executive equity awards.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially fostering better long-term decision-making. However, it also represents a minor potential for future dilution upon vesting.
• Management: Reinforces the director's commitment and compensation structure.

Next Steps

• Continued service by William James Farrell III to ensure vesting of the restricted shares over the next five years.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily serves to disclose insider ownership changes, which are generally expected.

Keywords

PRO DEX, PDEX, Form 4, insider transaction, restricted stock, equity grant, director compensation, stock award, vesting